Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-19-024839
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-16 19:44:16
Reporting Period:
2019-04-15
Accepted Time:
2019-04-16 19:44:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1269021 Portola Pharmaceuticals Inc PTLA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1187333 Hollings Renton C/o Portola Pharmaceuticals, Inc.
270 East Grand Ave.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-15 5,000 $9.00 14,000 No 4 M Direct
Common Stock Disposition 2019-04-15 4,600 $34.40 9,400 No 4 S Direct
Common Stock Disposition 2019-04-15 400 $35.07 9,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2019-04-15 5,000 $0.00 5,000 $9.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,000 2020-04-27 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,826 Indirect Held by The Renton Family Community Property Trust
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.9700 to $34.9650, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0000 to $35.1800, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4.
  4. The option, representing a right to purchase a total of 20,000 shares, became exercisable monthly over a two year period beginning on May 29, 2010.